<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193631</url>
  </required_header>
  <id_info>
    <org_study_id>PG-19-00A</org_study_id>
    <nct_id>NCT04193631</nct_id>
  </id_info>
  <brief_title>Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain</brief_title>
  <official_title>A Controlled-Dose Study Using A One Time Low Dose Cannabidiol Tablet For The Treatment of Mild to Moderate Musculoskeletal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pure Green</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pure Green</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether Pure Green tablets is a better pain reliever
      for the treatment of mild to moderate musculoskeletal pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2019</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of Pure Cannabidiol (CBD) tablets on safety in patient's with musculoskeletal pain using a self-reported pain scale score.</measure>
    <time_frame>1 Day</time_frame>
    <description>To evaluate the safety and efficacy of Pure Green Cannabidiol (CBD) sublingual tablets for the treatment of musculoskeletal pain by having patients evaluate their Numeric Pain Rating Scale (NPRS) score reported as 0-10 where 0 is no pain and 10 is the worst pain possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate efficacy of a low dose of Cannabidiol (CBD) in the treatment of mild to moderate musculoskeletal pain.</measure>
    <time_frame>1 Day</time_frame>
    <description>To explore the impact of Pure Green sublingual tablets on patient self-reported Numeric Pain Rating Scale (NPRS), as a route of administration and reduction in baseline pain scores.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Pure Green Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol (CBD)</intervention_name>
    <description>A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.</description>
    <arm_group_label>Pure Green Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female at least 21 years of age;

          2. Subject has mild to moderate musculoskeletal pain;

          3. Pain for greater than or equal to 10 days of each month for 3 months prior to study
             entry for which the pain requires treatment.

          4. Has an Numeric Pain Rating Scale (NPRS) score of 3 or greater,

          5. If female, subject is practicing an approved method of birth control throughout the
             study;

          6. Subject is willing and able to comply with all protocol-specified requirements;

          7. Subject is willing to take Pure Green tablets only and will not take any other pain
             medications,

          8. Subject is willing to provide his/her written informed consent to participate in the
             study as stated in the informed consent document.

          9. Subject is willing to document pain scale scores in a diary.

        Exclusion Criteria:

          1. Subject has any condition for which the investigator does not feel the participant
             should be enrolled due to possible safety or compliance issues;

          2. Subject has received treatment with an investigational drug or therapy within 30 days
             or 5 half-lives (whichever is longer) prior to Day 1.

          3. Subject has a known allergy to active or inert ingredients of Pure Green tablets;

          4. Subject is taking a concomitant medication or treatment that would complicate use or
             interpretation of the study drug's effects (examples include: Cannabis (marijuana) or
             any cannabinoid products including Cannabidiol (CBD) or Tetrahydrocannabinol (THC);
             Any drug or herbal product that influences the endocannabinoid system (ECS));

          5. Have serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or
             other medical or psychiatric condition that, in the opinion of the investigator, would
             compromise participation or be likely to lead to hospitalization during the course of
             the study.

          6. Have a history of recurrent seizures other than febrile seizures.

          7. Have current or pending disability compensation or litigation issues that may
             compromise response to treatment, in the opinion of the investigator.

          8. Have a diagnosis of inflammatory arthritis (that is, rheumatoid arthritis) or an
             autoimmune disorder (excluding inactive Hashimoto's thyroiditis).

          9. Use of acupuncture, chiropractic maneuvers, transcutaneous electrical nerve
             stimulation (TENS), or similar procedures aimed to relieve any kind of pain.

         10. Patients who are anticipated by the investigator to require use of analgesic agents
             including but not limited to non-steroidal anti-inflammatory drugs (NSAIDs),
             acetaminophen/paracetamol, and opioids, or other excluded medication for the duration
             of the study.

         11. Are unwilling or unable to comply with the data collection method used to record their
             patient rated outcome data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Kimless, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Kimless' Clinic</name>
      <address>
        <city>Chadds Ford</city>
        <state>Pennsylvania</state>
        <zip>19317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Madden K, van der Hoek N, Chona S, George A, Dalchand T, Baldawi H, Mammen G, Bhandari M. Cannabinoids in the Management of Musculoskeletal Pain: A Critical Review of the Evidence. JBJS Rev. 2018 May;6(5):e7. doi: 10.2106/JBJS.RVW.17.00153.</citation>
    <PMID>29787450</PMID>
  </reference>
  <reference>
    <citation>Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and Pain: A Clinical Review. Cannabis Cannabinoid Res. 2017 May 1;2(1):96-104. doi: 10.1089/can.2017.0017. eCollection 2017. Review.</citation>
    <PMID>28861509</PMID>
  </reference>
  <reference>
    <citation>Therapeutic Effects of Cannabis and Cannabinoids, National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press (US); 2017 Jan 12.</citation>
  </reference>
  <reference>
    <citation>Ware MA, Wang T, Shapiro S, Collet JP; COMPASS study team. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain. 2015 Dec;16(12):1233-1242. doi: 10.1016/j.jpain.2015.07.014. Epub 2015 Sep 16.</citation>
    <PMID>26385201</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CBD</keyword>
  <keyword>Cannabidiol</keyword>
  <keyword>Musculoskeletal Pain</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

